Myxovirus resistance protein A for discriminating between viral and bacterial lower respiratory tract infections in children – The TREND study

Rhedin, Samuel; Eklundh, Annika; Rinder, Malin Ryd; Peltola, Ville; Waris, Matti; Gantelius, Jesper; Lindh, Magnus; Andersson, Maria; Gaudenzi, Giulia; Mårtensson, Andreas; Nauclér, Pontus; Alfvén, Tobias

doi:10.1016/j.cmi.2022.05.008

Cited by 9 publications

(1 citation statement)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRP is an acute phase reactant that generally increases to higher levels with bacterial compared to viral infection, and MxA is a derivative of interferon α/β associated with viral infection. 10 , 11 …”

Section: Introductionmentioning

confidence: 99%

Use of the FebriDx® host-response point-of-care test may reduce antibiotic use for respiratory tract infections in primary care: a mixed-methods feasibility study

Wilcox,

Odeh,

Clark

et al. 2024

Journal of Antimicrobial Chemotherapy

View full text Add to dashboard Cite

Introduction FebriDx® is a CE-marked, single-use point-of-care test with markers for bacterial [C-reactive protein (CRP)] and viral [myxovirus resistance protein A (MxA)] infection, using finger-prick blood samples. Results are available after 10–12 min. We explored the usability and potential impact of FebriDx® in reducing antibiotic prescriptions for lower respiratory tract infection (LRTI) in primary care, and the feasibility of conducting a randomized controlled trial (RCT). Methods Patients (aged ≥1 year) with LRTI deemed likely to receive antibiotic prescription were recruited at nine general practices and underwent FebriDx® testing. Data collection included FebriDx® results, antibiotic prescribing plan (before and after testing) and re-consultation rates. Staff completed System Usability Scale questionnaires. Results From 31 January 2023 to 9 June 2023, 162 participants participated (median age 57 years), with a median symptom duration of 7 days (IQR 5–14). A valid FebriDx® result was obtained in 97% (157/162). Of 155 patients with available results, 103 (66%) had no detectable CRP or MxA, 28 (18%) had CRP only, 5 (3%) had MxA only, and 19 (12%) had both CRP and MxA. The clinicians’ stated management plan was to prescribe antibiotics for 86% (134/155) before testing and 45% (69/155) after testing, meaning a 41% (95% CI: 31%, 51%) difference after testing, without evidence of increased re-consultation rates. Ease-of-use questionnaires showed ‘good’ user-friendliness. Conclusions Use of FebriDx® to guide antibiotic prescribing for LRTI in primary care was associated with a substantial reduction in prescribing intentions. These results support a fully powered RCT to confirm its impact and safety.

show abstract

Section: Introductionmentioning

confidence: 99%